Clinical trials: Cholesterol; Metabolic Disorder
Atherosclerotic Cardiovascular Disease
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Study CKJX839B1FR01 in an In silico trial to predict the efficacy of Inclisiran therapy on major adverse cardiovascular events (MACE) and cardiovascular (CV) death in virtual patients with atherosclerotic cardiovascular disease…
- Trial name
- SIRIUS (NCT05974345)
- Testing
- Inclisiran sodium, Ezetimibe, Evolocumab
- Where
- France
- Volunteers
- 204,691 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia
A Multicenter, Active and Placebo-controlled Study of Enteric Coated Sevelamer in Patients With Mild to Moderate Hypercholesteremia
A total of 120 patients will be entered in this study to assess the safety and efficacy of enteric coated sevelamer (ECS) to lower LDL cholesterol.
- Trial name
- Sevelamer ECS (NCT00690937)
- Testing
- Enteric coated sevelamer, Colesevelam Cholestagel
- Where
- 8 sites in India
- Volunteers
- 120 people
- Sponsor
- Genzyme, a Sanofi Company
Heart Failure, High Blood Pressure
BVA-200 vs BVA-100 Validation Study
The proposed study is a prospective, observational, investigator and patient blinded study comparing the results of blood volume measurement using the FDA-cleared Daxor BVA-100 device to the Daxor BVA-200 device.
- Conditions
- Heart Failure, High Blood Pressure, High Cholesterol, Anemia
- Trial name
- NCT06227819
- Testing
- BVA-200
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Daxor Corporation
Hypertension, Hypercholesterolemia
Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin
This study will assess and compare the efficacy and safety of valsartan and the combination of valsartan and simvastatin in patients with high blood pressure and high cholesterol.
- Conditions
- Hypertension, Hypercholesterolemia, Dyslipidemia
- Trial name
- NCT00385931
- Testing
- Valsartan and simvastatin
- Where
- United States
- Volunteers
- 412 people
- Sponsor
- Novartis
LDL Cholesterol, Triglycerides
Safety and Efficacy of a Natural Health Product in Reducing Cholesterol and Triglyceride Levels.
The purpose of this study is to assess the safety and efficacy of a natural health product among participants with elevated LDL cholesterol and triglyceride levels.
- Trial name
- NCT01028274
- Testing
- Investigational Product 1, Investigational Product 2
- Where
- Canada
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Nordic Pharma, USA
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.
- Trial name
- CLEAR Wisdom (NCT02991118)
- Testing
- bempedoic acid
- Where
- 2 sites in United States
- Volunteers
- 779 people
- Sponsor
- Esperion Therapeutics, Inc.
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Fed
Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition
Galantamine Hydrobromide Tablets, Bioequivalence study of Dr. Reddy's under Fed condition.
- Trial name
- NCT01372306
- Testing
- Reminyl
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Primary Hypercholesterolemia or Mixed Hyperlipidemia
A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan
Cardiovascular disease (CVD) is a chronic non-communicable disease among the most common causes of death worldwide. Substantial reductions in risks of CVD can be achieved through the management of modifiable risk factors…
- Trial name
- CLEAR Taiwan (NCT06925100)
- Testing
- Bempedoic acid 180 mg tablet
- Where
- 3 sites in Taiwan
- Volunteers
- 180 people
- Sponsor
- Daiichi Sankyo
Dyslipidemia
12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia
The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia
- Trial name
- NCT00664859
- Testing
- LCP-AtorFen
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Veloxis Pharmaceuticals
Hypercholesterolaemia
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
This is a study to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naïve patients. Laroprovstat is a small molecule that reduces the amount of LDL-C in the blood.
- Trial name
- NCT07619131
- Testing
- Laroprovstat, Rosuvastatin 1, Rosuvastatin 2
- Where
- 152 sites in United States, Bulgaria and 9 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Efficacy and Safety of HEP-40 Chitosan for Mild to Moderately Elevated Cholesterol
Chitosan is a natural product that is produced commercially through the deacetylation of chitin, which is found in the exoskeleton of crustaceans. It has been suggested that chitosan has a lipid-lowering effect.
- Trial name
- HEP-40 (NCT00454831)
- Testing
- HEP-40 chitosan
- Where
- Canada
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- DNP Canada
Hypercholesterolemia
The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia
The main objectives of this study are to evaluate the efficacy and safety of combination therapy BMS-201038 (AEGR-733) plus ezetimibe vs. each agent given alone on LDL cholesterol and other lipoproteins over 12 weeks of therapy.
- Trial name
- NCT00405067
- Testing
- BMS-201038 (AEGR-733), Ezetimibe
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Dyslipidemias, Hypercholesterolemia
Cholesterol-lowering Effects of Plant Stanol Ester
Efficacy of plant stanols as esters on LDL-cholesterol reduction is well documented. LDL-cholesterol lowering efficacy of the ingredient administered in a smoothie is less well known.
- Conditions
- Dyslipidemias, Hypercholesterolemia, Hyperlipidemias
- Trial name
- NCT02316808
- Testing
- Plant stanol ester
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Raisio Group
Hypercholesterolemia
Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)
The purpose of this 24 week study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS) in subjects with elevated fat levels in their blood (dyslipidemia).
- Trial name
- NCT00080275
- Testing
- Niacin Extended-Release and simvastatin Tablets
- Volunteers
- 600 people
- Sponsor
- Kos Pharmaceuticals
To Determine Bioequivalence Under Fed Conditions
Bioavailability Study of Tramadol/APAP Tablets Under Fed Conditions
To compare the relative bioavailability of Kali and Ortho-McNeil's products
- Trial name
- NCT00652821
- Testing
- Tramadol/ APAP, Ultracet
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Par Pharmaceutical, Inc.
Dyslipidemias
Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study
To evaluate the percentage of Korean dyslipidemic subjects in the total group and each cardiovascular risk group achieving LDL-C target as defined by NCEP ATP Ⅲ criteria at starting doses of 10mg, 20mg and 40mg of atorvastatin…
- Trial name
- AT GOAL (NCT00540293)
- Testing
- Atorvastatin
- Where
- 20 sites in South Korea
- Volunteers
- 425 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Atherosclerotic Cardiovascular Disease
A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)
The purpose of this study was to assess the effectiveness of an "inclisiran first" implementation strategy (addition of inclisiran to maximally tolerated statin therapy immediately upon failure to achieve acceptable LDL-C with…
- Trial name
- V-INITIATE (NCT04929249)
- Testing
- Inclisiran
- Where
- 43 sites in United States
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Metabolic Syndrome
COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects
The purpose of this study is to compare the efficacy of treatment with rosuvastatin with atorvastatin in reducing Low density lipoprotein cholesterol over 6 weeks of treatment in subjects with metabolic syndrome.
- Trial name
- NCT00654485
- Testing
- Rosuvastatin, Atorvastatin
- Volunteers
- 940 people
- Sponsor
- AstraZeneca
Dyslipidemia
Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.
To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes
- Trial name
- NCT00326326
- Testing
- CP-778,875
- Where
- 31 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pfizer